CFO
NVCR icon

CVA Family Office’s NovoCure NVCR Stock Holding History

CVA Family Office’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23
Closed -$410 – 1399
2025
Q1 		$410 Buy
+23
New +$522 ﹤0.01% 1358
2022
Q3 		– Sell
-30
Closed -$2K – 911
2022
Q2 		$2K Buy
+30
New +$2.26K ﹤0.01% 834
2022
Q1 		– Sell
-45
Closed -$3K – 978
2021
Q4 		$3K Buy
+45
New +$4.52K ﹤0.01% 810

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CVA Family Office's NVCR Position: Q2 2025 in Review

CVA Family Office sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 23 shares — an estimated $410 sold.

CVA Family Office first reported a position in NVCR in Q4 2021 and held it in 3 quarters. The position peaked at $3K in Q4 2021. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • CVA Family Office reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • CVA Family Office sold 23 NovoCure shares in Q2 2025, an estimated $410.
  • CVA Family Office first reported a position in NovoCure in Q4 2021 and held it in 3 quarters.
  • CVA Family Office's NovoCure position peaked at $3K in Q4 2021.
  • 242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on CVA Family Office's 13F filing for Q2 2025, filed 31 Jul 2025.